Treatment of the SKOV3 human HER2-overexpressing ovarian cancer cell line with osthole, a traditional Chinese medicine, [21] and treatment of the AU565 human HER2-overexpressing breast cancer cell line with diosgenin, a plant-derived steroid, [22], and treatment of the BT474 human breast cancer xenografts in mice with G28UCM, a FASN inhibitor [23], decreases levels of pAkt and phosphorylated mTOR, but has no effect on pERK1/2 levels, and this results in reduced FASN expression and cell viability. This evidence concerns the gene FASN and breast cancer.